Thermo Fisher Scientific has entered into a collaboration agreement with Artificial to enable improved integration of software and robotics platforms to maximize COVID-19 testing throughput and efficiency.
Increasing COVID-19 testing throughput
Thermo Fisher Scientific, a global leader in serving science, and Artificial, developers of a first-of-its-kind flexible automation software, have announced a strategic technology collaboration to develop an integrated and comprehensive software automation platform for Thermo Fisher’s standardized COVID-19 Testing Platform. The integration is aimed at increasing COVID-19 testing throughput and supporting global healthcare initiatives.
As part of the joint effort, Artificial will provide access to its aLab Suite software, designed to seamlessly integrate with the Thermo Scientific Momentum Workflow software and robotics hardware. This will form part of the COVID-19 Testing Platform that will enable laboratories to upscale COVID-19 testing volumes fast and help reduce the spread of the disease and restore economies and communities.
The aLab Suite software enables the dynamic scheduling of protocol runs with batch optimizations to maximize the number of tests run. In addition, manual system set-up steps associated with Momentum process execution can be coordinated using aLab digital assistants to reduce the need for user input.
Minimizing errors and increasing productivity with automation
Furthermore, the use of aLab assistant’s digital twin of a COVID-19 testing system to guide lab technicians on where, when, and how to load system consumables will minimize errors resulting from manual tasks, ensuring sample safety and integrity and increasing system productivity.
Hansjoerg Haas, Senior Director and General Manager, Laboratory Automation, Thermo Fisher Scientific, stated:
“Laboratories performing COVID-19 testing continue to face the combined challenges of rapidly scaling workflows to meet the demands of communities while ensuring the accuracy and reproducibility of results. This collaboration enables biopharma and contract services companies to both simplify their lab technicians’ interactions with automated systems and more efficiently coordinate the use of their multiple Momentum automated systems, increasing productivity and minimizing user intervention to meet industry needs.”
David Fuller, CEO of Artificial commented:
“Artificial’s aLab Suite is a great addition to Thermo Fisher’s standardized COVID-19 Testing Platform solution in further enabling COVID-19 testing laboratories to easily and quickly scale their operations to meet the current demands. Our partnership with Thermo Fisher Scientific represents an exciting opportunity to improve COVID-19 testing throughput and further develop the aLab Suite to address the pain points of the life sciences market.”
As part of the collaboration, Thermo Fisher Scientific will utilize its extensive experience across life sciences to provide feedback on aLab Suite functionalities and capabilities to contribute to future product requirements and system specifications.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the global leader in serving science, with annual revenue exceeding $30 billion. The companies mission is to enable its customers to make the world healthier, cleaner and safer. Whether accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, Thermo Fisher Scientific is here to support its clients. With its international team of more than 80,000 the company delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
For more information, please visit www.thermofisher.com.
Source: SOURCE Thermo Fisher Scientific – https://thermofisher.mediaroom.com/2021-03-23-Thermo-Fisher-Scientific-Collaborates-with-Artificial-to-Enhance-COVID-19-Diagnostic-Testing-Solution